Early administration of the GIP receptor antagonist (Pro(3))GIP counters development of hyperglycaemia, glucose intolerance and insulin resistance in genetic obesity

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)0171
Issue numberSuppl.
Publication statusPublished (in print/issue) - Sept 2006

Bibliographical note

42nd Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), Copenhagen,
DENMARK, SEP 14-17, 2006

Cite this